Savant Capital LLC bought a new stake in shares of Boston Scientific Co. (NYSE:BSX – Free Report) during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund bought 6,164 shares of the medical equipment provider’s stock, valued at approximately $308,000.
A number of other hedge funds have also made changes to their positions in the stock. Great Valley Advisor Group Inc. increased its stake in Boston Scientific by 66.2% in the 1st quarter. Great Valley Advisor Group Inc. now owns 21,547 shares of the medical equipment provider’s stock valued at $1,078,000 after buying an additional 8,580 shares during the period. Strategy Asset Managers LLC grew its holdings in shares of Boston Scientific by 4.2% during the 1st quarter. Strategy Asset Managers LLC now owns 8,162 shares of the medical equipment provider’s stock valued at $408,000 after acquiring an additional 331 shares in the last quarter. Pacer Advisors Inc. increased its stake in shares of Boston Scientific by 1,597.5% in the first quarter. Pacer Advisors Inc. now owns 87,525 shares of the medical equipment provider’s stock worth $4,379,000 after acquiring an additional 82,369 shares during the last quarter. AllSquare Wealth Management LLC purchased a new stake in shares of Boston Scientific during the first quarter worth $51,000. Finally, Daiwa Securities Group Inc. boosted its position in Boston Scientific by 4.7% during the first quarter. Daiwa Securities Group Inc. now owns 142,823 shares of the medical equipment provider’s stock valued at $7,145,000 after purchasing an additional 6,386 shares during the last quarter. 92.20% of the stock is owned by hedge funds and other institutional investors.
Boston Scientific Price Performance
NYSE:BSX opened at $51.69 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.40 and a quick ratio of 0.89. The stock has a market cap of $72.37 billion, a P/E ratio of 86.15, a PEG ratio of 2.32 and a beta of 0.80. The company has a fifty day moving average price of $52.57 and a 200 day moving average price of $50.26. Boston Scientific Co. has a one year low of $37.74 and a one year high of $54.74.
Insider Transactions at Boston Scientific
In related news, EVP Arthur C. Butcher sold 6,697 shares of the company’s stock in a transaction on Wednesday, June 21st. The stock was sold at an average price of $53.80, for a total value of $360,298.60. Following the completion of the transaction, the executive vice president now directly owns 17,453 shares in the company, valued at $938,971.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Wendy Carruthers sold 11,671 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $53.24, for a total value of $621,364.04. Following the sale, the executive vice president now directly owns 72,847 shares in the company, valued at approximately $3,878,374.28. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 6,697 shares of the firm’s stock in a transaction that occurred on Wednesday, June 21st. The stock was sold at an average price of $53.80, for a total value of $360,298.60. Following the transaction, the executive vice president now owns 17,453 shares of the company’s stock, valued at approximately $938,971.40. The disclosure for this sale can be found here. In the last quarter, insiders have sold 176,779 shares of company stock valued at $9,371,164. 0.71% of the stock is owned by corporate insiders.
Analyst Upgrades and Downgrades
BSX has been the subject of a number of recent research reports. Royal Bank of Canada raised their price target on Boston Scientific from $56.00 to $58.00 in a research note on Wednesday, July 12th. TheStreet upgraded shares of Boston Scientific from a “c+” rating to a “b” rating in a research note on Tuesday, May 30th. BTIG Research increased their price target on shares of Boston Scientific from $56.00 to $57.00 in a research note on Monday, July 17th. Piper Sandler lifted their price objective on shares of Boston Scientific from $58.00 to $62.00 in a research note on Thursday, July 6th. Finally, Mizuho increased their target price on shares of Boston Scientific from $52.00 to $56.00 in a research report on Tuesday, April 18th. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $58.20.
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
Featured Articles
- Five stocks we like better than Boston Scientific
- What is a Stock Market Index and How Do You Use Them?
- MarketBeat Week in Review – 7/24 – 7/28
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Can SAIA Continue its Stratospheric Rally?
- Bank Stocks – Best Bank Stocks to Invest In
- Why Markets Are Loving Exxon Mobil, Despite The Earnings Dip
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.
